checkAd
    Regeneron Pharmaceuticals Aktie
    980,57
     
    USD
    -0,33 %
    -3,23 USD
    Letzter Kurs 23:20:00 Nasdaq
    980,57
     
    USD
    500 STK
    Geldkurs 22:02:00
    981,15
     
    USD
    200 STK
    Briefkurs 22:02:00
    ISIN: US75886F1075 · WKN: 881535 · SYM: RQP · USA

    Neueste Nachrichten

    Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo (cemiplimab) to be Reported at ASCO
    23:03 Uhr · globenewswire · Regeneron Pharmaceuticals
    Dupixent (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
    20.05.24 · globenewswire · Regeneron Pharmaceuticals
    More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
    17.05.24 · globenewswire · Regeneron Pharmaceuticals
    Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
    16.05.24 · Business Wire (engl.) · Regeneron Pharmaceuticals
    Dupixent (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
    13.05.24 · globenewswire · Regeneron Pharmaceuticals
    Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
    08.05.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron Announces Investor Conference Presentations
    06.05.24 · globenewswire · Regeneron Pharmaceuticals
    Chartgalerie - Top / Flop Aktien Wochenrückblick Kalenderwoche 18/24
    04.05.24 · wO Chartvergleich · American Express
    Regeneron Reports First Quarter 2024 Financial and Operating Results
    02.05.24 · globenewswire · Regeneron Pharmaceuticals
    EYLEA HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
    29.04.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
    25.04.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
    24.04.24 · globenewswire · Regeneron Pharmaceuticals